Clinical Research Directory
Browse clinical research sites, groups, and studies.
Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
Sponsor: National Institute of Cardiovascular Diseases, Pakistan
Summary
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.
Official title: Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction: An Open Label, Randomized Clinical Trial (POTAMI)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
472
Start Date
2024-12-02
Completion Date
2025-11-30
Last Updated
2024-12-19
Healthy Volunteers
No
Interventions
Apixaban 2.5 MG PO BID
Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT.
Control (Standard treatment)
DAPT plus guideline directed medical therapy
Locations (1)
NICVD Pakistan
Karachi, Sindh, Pakistan